BIC | ITALY 8-10 SEPTEMBER 2023
INTERNATIONAL CONFERENCE | WWW.BICCONFERENCE.ORG

9th September - h. 17:30-18:30

CHAIRS:	S. Lacroix (France)	M. Makris (UK)	C. Denis (France)	P. Lenting (France)
	PRINCE OF SALINA - IL GATTOPARDO	DONNA FRANCA FLORIO	KING FREDERICK II "STUPOR MUNDI"	LUIGI PIRANDELLO
17:30	PO 01 - HAEMOPHILIA SPECIFICATION ANALYSIS AND DETECTION OF FVIII IN LSEC-LIKE ENDOTHELIAL CELLS FROM HEALTHY DONOR AND HA PATIENTS WITH NONSENSE MUTATIONS - P. Chawla (Germany)	PO 25 - HEMOPHILIA therapy EMICIZUMAB WASTE ESTIMATION FOR TREATING PEOPLE WITH HEMOPHILIA A AND INHIBITORS WHO FAILED IMMUNE TOLERANCE INDUCTION ACCORDING TO THE CURRENT BRAZILIAN PUBLIC HEALTH PROTOCOL - R.M. Camelo (Brazil)	PO 37 - VON WILLEBRAND DISEASE PERSONALIZED GENE THERAPY DEVELOPMENT FOR THE SEVERE VWD TYPE 3 PATIENT MUTATION P.M771V - I. Bär (The Netherlands)	PO 31 - THROMBOTIC MICROANGIOPATHIES BORTEZOMIB IN MULTI-REFRACTORY IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA: AN ITALIAN MULTICENTER SURVEY - Juri A. Giannotta (Italy)
17:40	PO 02 - HAEMOPHILIA FVIII DEFICIENT BONE PROGENITOR CELLS DISPLAY AN ALTERED *IN VITRO* DIFFERENTIATION CAPABILITY INTO OSTEOBLASTS AND OSTEOCLASTS - P.E Di Simone (Italy)	PO 26 - HEMOPHILIA therapy MATCHING ADJUSTED INDIRECT COMPARISONS BETWEEN PERSONALISED PROPHYLAXIS WITH SIMOCTOCOG ALFA VERSUS STANDARD PROPHYLAXIS WITH EMICIZUMAB IN ADULTS WITH SEVERE HAEMOPHILIA A - C. Kessler (Unites States)	PO 38 - VON WILLEBRAND DISEASE PERMANENT EX-VIVO RESCUE OF VWF PHENOTYPE IN VWD TYPE 3 MODELS - A. Barraclough (The Netherlands)	PO 33 - THROMBOTIC MICROANGIOPATHIES PAD4 PREFERENTIALLY CITRULLINATES ARG636 OF ADAMTS13 AND CLUSTERED ARGININE RESIDUES IN THE ALPHA CHAIN OF FIBRINOGEN - T. Arfman (The Netherlands)
17:50	PO 03 - HAEMOPHILIA THROMBODYNAMICS AND FXIA INITIATED THROMBIN GENERATION: NOVEL ASSAYS FOR DIAGNOSTIC EVALUATION OF HAEMOPHILIA A PATIENTS - R.A. Arisz (The Netherlands)	PO 22 - HEMOPHILIA therapy CONCIZUMAB PROPHYLAXIS IN PATIENTS WITH HAEMOPHILIA A OR B WITH INHIBITORS: EFFICACY AND SAFETY EXPLORATORY RESULTS FROM THE PHASE 3 EXPLORER7 STUDY - G. Castaman (Italy)	PO 39 - VON WILLEBRAND DISEASE CLINICAL AND PHENOTYPIC PRESENTATION AND UNDERLYING MECHANISMS IN PATIENTS WITH LOW VWF - O. Seidizadeh (Italy)	PO 34 - THROMBOTIC MICROANGIOPATHIES DETAILED INVESTIGATION OF ADAMTS13 ACTIVITY AND ANTI-ADAMTS13 IGG ANTIBODY LEVELS IN IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA PATIENTS TREATED WITH CAPLACIZUMAB - G. Sinkovits (Hungary)
18:00	PO 04 - HAEMOPHILIA INCIDENCE AND CHARACTERISTICS OF ANAEMIA IN ADULT HAEMOPHILIA PATIENTS: A SINGLE-CENTRE STUDY - P. Miljic (Serbia)	PO 17 - HEMOPHILIA therapy INHIBITOR PREVENTION IS POSSIBLE WITH USING PLASMA-DERIVED FVIII PRODUCTS IN PUP PATIENTS: ONE CENTER EXPERIENCE - K. Kavakli (Turkey)	PO 42 - VON WILLEBRAND DISEASE CURRENT MANAGEMENT OF SEVERE TYPE 3 VWD: NEW INSIGHTS FROM GENOTYPIC AND PHENOTYPIC CHARACTERIZATION OF A LARGE COHORT OF PATIENTS ENROLLED INTO 3WINTERS-IPS - A.B. Federici (Italy)	PO 35 - THROMBOTIC MICROANGIOPATHIES FRAGMENTED RED BLOOD CELLS (FRC) – A USEFUL PARAMETER TO EXCLUDE THE PRESENCE OF SCHISTOCYTES ON THE BLOOD SMEAR? - M. Miloš (Croatia)
18:10	PO 15 - HEMOPHILIA inhibitor NO RELAPSE IN PATIENTS WITH PREVIOUS INHIBITORS WHO SWITCHED TO EFMOROCTOCOG ALFA, A RECOMBINANT FACTOR VIII FC, IN NON-INTERVENTIONAL PHASE 4 STUDIES - S. Lethagen (Sweden)	PO 29 - HEMOPHILIA therapy ENSURING FAIR AND JUST ACCESS TO NOVEL THERAPIES TO ENSURE THE HEALTH AND WELL- BEING OF PEOPLE LIVING WITH HEMOPHILIA GLOBALLY: ETHICAL AND JUST DISTRIBUTION OF RESOURCES FOR A RARE DISEASE - L. Valentino (United States)	PO 44 - VON WILLEBRAND DISEASE EFFICACY AND SAFETY OF VWF CONCENTRATES IN A COHORT OF 93 PATIENTS WITH TYPE 3 VON WILLEBRAND DISEASE ENROLLED IN 3WINTERS-IPS: RESULTS OF THE 2-YEAR PROSPECTIVE CLINICAL OBSERVATION - A.B. Federici (Italy)	PO 46 - MISCELLANEA PHENOTYPE AND GENOTYPE CHARACTERIZATION OF PATIENTS WITH CONGENITAL FIBRINOGEN DEFICIENCIES: A RETROSPECTIVE ANALYSIS OF THE PRO-RBDD DATABASE - R. Palla (Italy)
18:20	POSSIBLE REPEAT TIME	POSSIBLE REPEAT TIME	POSSIBLE REPEAT TIME	PO 09 - HAEMOPHILIA IMPACT OF FIX ACTIVITY ASSAY RESULTS DETERMINED WITH ONE-STAGE CLOTTING AND CHROMOGENIC ASSAYS ON THE CLASSIFICATION OF HAEMOPHILIA B - M. Miloš (Croatia)